Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney removal after immunotherapy may offer cure for select patients

NCT ID NCT06882486

Cure Sponsor: Institut Paoli-Calmettes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether removing the kidney after successful immunotherapy can help patients with metastatic kidney cancer stop all treatment and stay cancer-free. About 60 adults whose tumors have shrunk significantly with immunotherapy will either have surgery and stop therapy, or continue therapy without surgery. The goal is to see if this approach can lead to long-term remission and potentially a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient aged ≥ 18 years 2. Diagnosed with synchronous metastatic kidney cancer 3. With primary tumor still in place (no primary cytoreductive nephrectomy) 4. Having received systemic ICI immunotherapy-based combination therapy 5. In CR or mPR (defined as \>75% response in metastatic lesions from baseline) according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), excluding the primary renal lesion. 6. Signed consent to participate 7. Affiliated to the national social security scheme or beneficiaries of such a scheme Exclusion Criteria: 1. Women who are or may become pregnant (without effective contraception) or who are breast-feeding. 2. Person in an emergency situation or unable to give consent. 3. An adult under legal protection (guardianship, curators or safeguard of justice), 4. Inability to undergo medical follow-up for geographical, social or psychological reasons. 5. Patients who have undergone prior cytoreductive nephrectomy 6. Patients considering nephrectomy for symptomatic disease, but without major response (CR or mPR) in metastatic disease 7. Patients with non-metastatic disease at diagnosis who have received ICI in a neo-adjuvant setting 8. Patients with contraindications to surgery or ineligible for nephrectomy 9. Patients not wishing to undergo nephrectomy 10. Patients with end-stage renal disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

kidney cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institut Paoli-Calmettes

    RECRUITING

    Marseille, Institut Paoli-calmettes, 13273, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.